CDD Vault Drug Discovery Data Platform

Collaborative Drug Discovery, Inc. (CDD) is a software company based at 1633 Bayshore Highway, Burlingame, California, with a founding vision dating from 2004. It provides a hosted database for biotech firms, pharma groups, contract research organisations and academic labs that need to manage and securely share chemical and biological research data with partners.

CDD Vault combines Registration, Activity and Visualization, Assays, an ELN, Inventory, Curves, AI and Automation modules in one web platform. Scientists register compounds and biologics, capture assay results, plot and mine data, and apply built-in generative and deep learning tools. Through a 2026 agreement with Eli Lilly, biotech users that opt in can use select Lilly TuneLab predictive models trained on Lilly's proprietary research data inside CDD Vault's core and AI modules. Users include Eli Lilly, Jubilant Biosys, X-Chem, VIB and the Bill and Melinda Gates Foundation.

• Registration: register small molecules, biologics and mixtures as secure data assets.
• Activity and visualization: capture assay results and plot or mine structure-activity data.
• ELN and inventory: electronic lab notebook linked to sample and reagent inventory.
• Assays and curves: assay informatics with dose-response curve fitting.
• AI module: built-in generative and deep learning tools plus select Lilly TuneLab predictive models.
• Automation and API: workflow automation and API for instrument and system integration.

Vietnamese university and institute groups working on natural-product drug discovery can register compounds and share assay data with foreign partners. Local pharmaceutical R&D centres can apply predictive models to prioritise compounds before synthesis. Contract chemistry and biology service providers can deliver results to clients through a shared vault.

Hosted delivery lets small biotech teams and academic groups start without on-premise servers or IT staff. Secure partitioning allows controlled data sharing with CROs and collaborators. Access to Lilly TuneLab models trained on Lilly's proprietary research data gives smaller companies predictive models they could not train themselves. A free trial with real data lets labs test the platform before buying.

Drug discovery is moving to externalised networks of biotechs, CROs and academic partners, which need shared, secure data platforms and access to pre-trained AI models. In Asia, contract research providers and university drug discovery groups, including in Vietnam, increasingly collaborate with foreign partners and need structured compound and assay data.

Collaborative Drug Discovery, Inc., Burlingame, California, USA; founding vision dates from 2004. Agreement with Eli Lilly in May 2026 to integrate Lilly TuneLab. Customers and users named on the site include Eli Lilly, Jubilant Biosys, X-Chem, MoA Technology, VIB, Indiana University, Plexium and Standigm.